1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

F-star asset-centric spin-out to target HER2

 
• By Gemma Collier

Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.

Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.

The asset-centric approach is designed to create opportunities with this fundraising process. It involves placing each of F-star's assets in its own vehicle company to allow the firm more flexibility...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

More from Therapy Areas

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.